1. Home
  2. IGC vs ETHZW Comparison

IGC vs ETHZW Comparison

Compare IGC & ETHZW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IGC
  • ETHZW
  • Stock Information
  • Founded
  • IGC 2005
  • ETHZW N/A
  • Country
  • IGC United States
  • ETHZW United States
  • Employees
  • IGC N/A
  • ETHZW N/A
  • Industry
  • IGC Biotechnology: Pharmaceutical Preparations
  • ETHZW Biotechnology: Pharmaceutical Preparations
  • Sector
  • IGC Health Care
  • ETHZW Health Care
  • Exchange
  • IGC Nasdaq
  • ETHZW Nasdaq
  • Market Cap
  • IGC 39.8M
  • ETHZW 35.3M
  • IPO Year
  • IGC N/A
  • ETHZW 2017
  • Fundamental
  • Price
  • IGC $0.41
  • ETHZW $0.07
  • Analyst Decision
  • IGC Strong Buy
  • ETHZW
  • Analyst Count
  • IGC 2
  • ETHZW 0
  • Target Price
  • IGC $4.00
  • ETHZW N/A
  • AVG Volume (30 Days)
  • IGC 1.3M
  • ETHZW N/A
  • Earning Date
  • IGC 11-11-2025
  • ETHZW N/A
  • Dividend Yield
  • IGC N/A
  • ETHZW N/A
  • EPS Growth
  • IGC N/A
  • ETHZW N/A
  • EPS
  • IGC N/A
  • ETHZW N/A
  • Revenue
  • IGC $1,327,000.00
  • ETHZW N/A
  • Revenue This Year
  • IGC $15.26
  • ETHZW N/A
  • Revenue Next Year
  • IGC $3.41
  • ETHZW N/A
  • P/E Ratio
  • IGC N/A
  • ETHZW N/A
  • Revenue Growth
  • IGC 24.95
  • ETHZW N/A
  • 52 Week Low
  • IGC $0.25
  • ETHZW N/A
  • 52 Week High
  • IGC $0.50
  • ETHZW N/A
  • Technical
  • Relative Strength Index (RSI)
  • IGC 51.81
  • ETHZW N/A
  • Support Level
  • IGC $0.38
  • ETHZW N/A
  • Resistance Level
  • IGC $0.44
  • ETHZW N/A
  • Average True Range (ATR)
  • IGC 0.03
  • ETHZW 0.00
  • MACD
  • IGC -0.00
  • ETHZW 0.00
  • Stochastic Oscillator
  • IGC 32.33
  • ETHZW 0.00

About IGC IGC Pharma Inc.

IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.

Share on Social Networks: